Novartis was created in 1996 through the merger of 2 Swiss companies, Ciba-Geigy and Sandoz. Completed a complex three-part transaction with GSK in 2015: GSK acquired Novartis' global vaccines business, Novartis bought GSK's oncology business, and the two companies formed a Consumer Healthcare joint venture. Novartis now operates in just four areas - novel drugs, its Alcon eye care products, its Sandoz generic drugs business, and the GSK joint venture.
This company received the second highest score in the Access to Medicine Index 2018, a ranking of the world's largest pharmaceutical companies on their efforts to increase access to medicine in developing countries.
[Source 2018][More on Human Rights]
The Global 100 Most Sustainable Corporations in the World list is an extensive data-driven corporate sustainability assessment. The ranked companies are leaders in the field of a sustainable business approach. The efficiency of a company's energy, water, CO2 and waste management is measured in relation to its total sales volume. The disclosure of that information is a pre-condition for the assessment. This company ranked #98 in the 2016 Global 100.
[Source 2016][More on Sustainability Reporting]
This company received a score of 2.5/100 (retrieved 14-Feb-2018) in the Corporate Information Transparency Index (CITI), a system for evaluating supply chain practices in China, particularly in regards to environmental management and water pollution. Scores are calculated using government compliance data, online monitoring data, and third-party environmental audits, as well as trends in the environmental performance of factories in the company's supply chains.
[Source 2018][More on Habitats]
As You Sow's 2018 report, Mining the Disclosures, is a deep analysis of 206 companies' human rights performance in relation to sourcing conflict minerals from the Democratic Republic of the Congo (DRC). This company's score was below 40% (Weak).
[Source 2018][More on Human Rights]
In 2015 the US Justice Department fined this company US$390 million for granting kickbacks to pharmacies that recommended the company's drugs. In a settlement deal, Novartis admitted that it gave specialty pharmacies exceptional rebates and patient referrals in exchange for recommending Exjade, which treats excess iron in blood, and Myfortic, an anti-rejection drug for kidney transplant recipients. The civil settlement is smaller than the $3.3 billion fine the government originally sought in the case.
[Source 2015][More on Governance]
This company received a score of 44.6/100 in the Newsweek Green Ranking 2017, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
[Source 2017][More on Sustainability Reporting]
Public Eye Awards are given to companies with the worst record in terms of environmental pollution and human rights violations. Novartis received the award in 2007 for causing the halt of the production of generic cancer drugs in India. Listed under information due to age of award.
[Source 2007][More on Human Rights]
Trileptal is an anti-convulsant and mood-stabilizer that is used to treat epilepsy and bipolar disorders. The drug was designed to subdue partial seizures, or ones that begin in a limited part of the brain. However, manufacturer Novartis marketed Trileptal and five other drugs Diovan, Exforge, Sandostatin, Tekturna and Zelnorm for treatments not approved by the FDA, including relieving psychiatric symptoms and pain. The false promotions led to false claims in federal health care plans. Novartis also was accused of paying kickbacks to physicians who prescribed the six drugs. Novartis pleaded guilty to a misdemeanor and paid $185 million in 2010. [Listed under Information due to age of court finding]
[Source 2010][More on Irresponsible marketing]
Novartis invested heavily in xenotransplantation research in the late 1990's using transgenic pigs, but stopped its research in the early 2000s. This research caused the deaths of thousands of animals and cost millions of dollars trying to develop animal organs for transplantation into humans. All attempts to carry out animal-to-human organ transplants failed.
[Source 2015][More on Animal Rights]
Novartis Boycott was a campaign undertaken by the DRUG ACTION FORUM, India against Novartis, a pharmaceutical company dedicated to establishing a patent protected market in India, by the removal of barriers to competition. Novartis challenged the rejection of grant for its anti-cancer drug in both the High Court and the Supreme Court of India. The boycott campaign was withdrawn when Novartis lost its Supreme Court case.
[Source 2007][More on Governance]
This company is listed on the Federal Contractor Misconduct Database as having 11 instances of misconduct since 1995 amounting to US$791 million in penalties. Instances include false claims, discrimination and illegal marketing.
[Source 2014][More on Governance]
As listed on the We Mean Business website, this company has committed to the following climate action initiatives: adopt a science-based emissions reduction target; put a price on carbon;
[Source 2017][More on Climate Change]
California, the UK and Australia have all enacted legislation requiring companies operating within their borders to disclose their efforts to eradicate modern slavery from their operations and supply chains. Follow the link to see this company's disclosure statement.
[Source 2017][More on Human Rights]
The Corporate Research Project's Corporate Rap Sheets are dossiers summarising the most significant crimes, violations and other questionable activities of the world's largest and most controversial companies. Follow link to see this company's Corporate Rap Sheet. " The businesses that went into the creation of Novartis have frequently been at the center of controversies concerning unsafe drugs and pesticides, price-gouging, improper marketing and toxic dumping. The company also had to pay more than $150 million to settle a sex discrimination lawsuit in the United States. Novartis was widely criticized for its drawn-out but ultimately unsuccessful battle against an Indian patent policy designed to make lower-cost drugs more widely available in poor countries. "
|Company Structure||Public company|
|Revenue||US$57.9 billion in 2013|
|# Employees||135,696 in 2013|
|Subsidiaries||Novartis Consumer Health Australiasia
Novartis Pharmaceuticals Australia Pty Ltd
Roche Holding Ltd (33% owned)
- Roche Products Pty Ltd
GSK Consumer Healthcare (37% owned)
- GlaxoSmithKline Australia Pty Ltd
Products / BrandsNovartis Australia
Eno Digestive Care
Horlicks Milk Flavouring
Lamisil Foot Care
Nicabate Quit Smoking
Otrivin Cold & Flu
Panadol Pain Relief
Panadol Cold & Flu
Panafen Pain Relief
Sensodyne Dental Floss
Zovirax Lip Care